Prevention of Russian influenza by amantadine
A. S. Monto, R. A. Gunn, M. G. Bandyk and C. L. King
We tested the effectiveness of amantadine hydrochloride in prevention of
illness and infection caused by Russian (h1n1) influenza. The trial lasted
seven weeks and was double-blind and placebo controlled. The dosage used
was 200 mg daily. Efficacy in prevention of serologically confirmed
clinical influenza was 70.7%. Efficacy in prevention of infection,
symptomatic or asymptomatic, was 39.4%. Side effects seen were all mild,
began within two days of the start of the trial, and terminated rapidly on
cessation of prophylaxis. The withdrawal rate attributable to use of
amantadine was 6.2%. Those who continued to receive prophylaxis for the
remainder of the trial did not exhibit excess side effects. It is concluded
that amantadine is safe and effective in prophylaxis of H1N1 strains, as
has been shown previously for other subtypes of A influenza.
